Worse Odor Identification is Associated with Poorer Cognitive Function in pre-MCI Individuals: A Meta-analysis

Jobin, Benoît [1,2,3], **Zigrand,** Coline [4,6], **Frasnelli**, Johannes [2,5,6], **Boller**, Benjamin [1,2] & **Albers**, Mark W [3,7]

[1] Department of Psychology, Université du Québec à Trois-Rivières, Qc, Canada.
[2] Research Centre of the Institut universitaire de gériatrie de Montréal, Qc, Canada.
[3] Department of Neurology, Massachusetts General Hospital, Boston, MA, United States.
[4] Department of Psychology, Université du Québec à Montréal, Qc, Canada.
[5] Department of Anatomy, Université du Québec à Trois-Rivières, Qc, Canada.
[6] Research Centre of the Hôpital du Sacré-Cœur de Montréal, Qc, Canada.
[7] Harvard Medical School, Boston, MA, United States.

Corresponding author: Benoît Jobin, benoit.jobin@uqtr.ca, +1 (514) 606-1530, 3351 Boulevard des Forges, C.P. 500 Trois-Rivières (Québec) G9A 5H7, Local 3470 Léon-Provencher.

Abstract

Introduction: Odor identification correlates with Alzheimer's disease (AD) biomarkers, and its decline may emerge before measurable cognitive deficits—as early as the subjective cognitive decline (SCD) stage. We aimed to compare odor identification between SCD and cognitively normal (CN) stages and investigate whether cognitive differences moderate olfactory deficits.

Methods: A systematic search of four databases identified studies assessing olfactory identification and cognitive screening in individuals aged 50 years or older. A random-effects meta-analysis was performed on 11 studies (660 SCD, 574 CN).

Results: Individuals with SCD exhibited lower olfactory identification scores compared to CN participants (SMD = -0.67, 95%CI [-1.31, -0.03], p = .04). Meta-regression analyses indicated that larger cognitive differences between groups were associated with more pronounced olfactory deficits (β = -1.79, p = .02).

Discussion: Worse cognition in pre-MCI individuals is associated with impaired odor identification, supporting the potential role of odor identification as a screen for AD biomarkers and future cognitive decline.

Keywords: Subjective cognitive decline, Alzheimer's disease, Biomarker, Olfaction, Smell, Olfactory identification, Meta-Analysis.

1. Background

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the accumulation of amyloid-β plaques and tau neurofibrillary tangles, followed by widespread neurodegeneration and cognitive decline, culminating in dementia.[1] Early identification of individuals at risk for AD is critical for timely intervention, particularly as the disease progresses over decades before the occurrence of first cognitive deficits,[2–4] and as therapies targeting amyloid pathology and other early pathological stages become available.[5,6] Subjective cognitive decline (SCD) refers to self-reported cognitive decline in the absence of measurable deficits on neuropsychological tests.[7] SCD is considered the first symptom of AD, appearing at stage 2 of the disease,[1,8] and has been associated with an increased risk for the development of mild cognitive impairment (MCI) and progression to the dementia stages of the disease.[9,10]

While SCD is associated with an increased risk of cognitive decline, not all individuals reporting SCD will decline.[10] Furthermore, the presence of AD biomarkers among individuals with SCD varies considerably, ranging from 10% to 76%.[9,11,12] This broad variability suggests a lack of diagnostic precision and highlights the heterogeneity of SCD as a clinical entity. Therefore, SCD alone is not sufficient to predict cognitive decline, necessitating the identification of additional reliable, and easily accessible markers that can improve the specificity of early risk assessment.

One promising candidate for preclinical AD detection is odor identification impairment. Multiple studies have demonstrated that odor identification is impaired at the dementia[13] and MCI[14] stages and is thought to emerge even before measurable episodic memory deficits.[15,16] The primary olfactory cortex morphometry is damaged in MCI[17–19] and olfactory identification is

associated with hippocampal volume and entorhinal cortex thickness in patients with MCI[20–26] and individuals with SCD.[27] Olfactory identification is also associated with longitudinal tau pathology accumulation within the central olfactory system in cognitively normal individuals.[28] Several longitudinal studies have demonstrated that olfactory identification scores are associated with cognitive decline in cognitively normal individuals[29–33] and conversion from MCI to dementia stage.[34,35] Taken together, these findings suggest that olfactory impairment may represent a subtle, early marker of neurodegeneration, and could have predictive value in the detection of preclinical AD.

A prior meta-analysis[36] suggested a trend toward lower olfactory identification scores in individuals with SCD compared to cognitively normal (CN) older adults. The number of included studies was small (k = 5), limiting the analysis of potential moderators and the interpretation of the conclusions. Since its publication, several new studies have examined olfactory function in SCD. With the advent of treatments that mitigate the burden of amyloid pathology at the MCI and early dementia stages, it is crucial to identify low-cost, non-invasive, and accessible signs and markers for AD that manifest prior to the onset of measurable cognitive deficits, particularly before the progression to MCI. Olfactory testing may thus offer a valuable complement to existing cognitive screening tools and could aid in stratifying risk in clinically normal individuals reporting cognitive concerns. The aim of the meta-analysis was (1) to compare odor identification between older adults with SCD and CN older adults without cognitive complaint, and (2) to evaluate the magnitude of olfactory identification impairment in SCD by comparing the effect sizes of olfactory differences with those observed in general cognitive screening measures (e.g., Montreal Cognitive Assessment - MoCA,[37] Mini-Mental State Examination - MMSE[38]).

2. Methods

The protocol of this meta-analysis was not registered.

2.1 Study Eligibility Criteria

Eligible studies included a direct comparison of odor identification scores between individuals with SCD and CN participants without cognitive impairment or cognitive complaint, with both groups including men and women aged 50 years and older. The definition of SCD was based on two core criteria: (1) self-reported cognitive decline relative to a previous performance level and (2) normal cognitive performance on standardized cognitive tests, such as the MMSE or the MoCA to exclude MCI. CN participants were required to be CN without objective cognitive impairment (i.e., scoring > -1.5 standard deviations on cognitive tests) and without self-reported complaints of cognitive decline. Studies were excluded if participants were younger than 50 years of age, had a diagnosed cognitive impairment, or had a psychiatric or neurological condition that could affect cognitive or olfactory function.

Outcome. Eligible studies had to assess olfactory identification using a validated olfactory identification test to be included in the meta-analysis. The eligible tests included the Sniffin' Sticks Identification Test (SSIT),[39] the Odor Perception Identification Test (OPID)[20]/ the AROMHA Brain Health Test,[40] the University of Pennsylvania Smell Identification Test (UPSIT),[41] or the Cross-Cultural Smell Identification Test (CC-SIT).[42] Similarly, eligible studies were required to include a measure of general cognition functioning using a standard screening test (MoCA or MMSE)[37,38] to allow for effect size comparisons across cognitive and olfactory measures.

2.2 Search Strategy and Information Source.

A systematic literature search was conducted to identify relevant studies published up to February 1st, 2025. The search was conducted in the PsycNET, PubMed, Academic Search Complete (EBSCO), and Scopus databases. The following keywords and Boolean operators were used: ("SCD" OR "subjective cognitive decline" OR "subjective cognitive impairment" OR "subjective memory impairment" OR "subjective memory decline" OR "cognitive complaint*" OR "memory complaint*" OR "cognitive concerns" OR "memory concerns") AND ("olfac*" OR "smell" OR "olfactory dysfunction" OR "olfactory impairment"). Studies had to be published in English.

After the removal of 106 duplicates, 113 titles and abstracts were screened for eligibility. We excluded studies that were unrelated to the research question, review articles, case studies, qualitative studies, or the absence of a control group. After the initial screening, 40 studies were identified as potentially eligible and were further assessed for inclusion. After reviewing full-text articles, 11 studies and 13 reports met the inclusion criteria (Figure 1).



Figure 1. PRISMA Flow Diagram of Study Selection.

The figure illustrates the study selection process based on PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.

2.3 Risk of Bias Assessment

The methodological quality of each included study was assessed using the Newcastle-Ottawa Scale (NOS)**,** as recommended.[43] The NOS[44] is a tool designed to evaluate the quality of non-randomized case-control studies in meta-analyses, assessing three key domains: participant selection, comparability between groups, and outcome ascertainment. The scoring system ranges from 0 to 9 points, with higher scores indicating higher study quality. Studies scoring 0–3 were considered at high risk of bias, 4–6 at moderate risk, and 7–9 at low risk. The risk of bias for each study was independently evaluated by two reviewers (BJ and CZ). If disagreement emerged, the most conservative score was assigned. No major disagreements occurred during this process, and no studies were excluded based on quality assessment. The final risk of bias scores for each included study are summarized in Supplementary Table 1.

2.4. Statistical Analyses

We conducted random-effects meta-analyses using the *meta* package in R. We standardized mean differences (SMD, Hedges' *g*) for each study by comparing the mean scores of SCD and CN groups. To improve variance estimation, we performed random-effects model using the Hartung-Knapp adjustment, with effect sizes weighted by the inverse variance of their standard errors. This approach provides robust confidence intervals and improves statistical inference, especially in meta-analyses with small numbers of studies or high heterogeneity.[45–47] We assessed heterogeneity using Cochran's Q statistic, Higgins' I^2 index, and τ^2 to quantify between-study variability. High heterogeneity ($I^2 > 75\%$) prompted further investigation through meta-regression. We conducted meta-regression analyses to examine the potential moderating effects of *age*, *sex proportion* (female), *educational level* (years), and *test modality* on effect sizes.

We assessed potential publication bias using visual inspection of funnel plots, Egger's regression test, and the trim-and-fill method. Funnel plot asymmetry and Egger's test *p*-values < .05 were considered indicative of potential bias. We used the trim-and-fill method to impute missing studies and adjust the pooled effect size under the assumption of publication bias. Statistical significance was set at $p < .05$ for all analyses.

3. Results

3.1 Study selection and characteristics

A total of 11 studies met the inclusion criteria, combining 660 individuals with SCD and 574 CN participants (see Figure 1 & Table 1). Two reports/articles used the same sample, therefore this dataset counted as a single study to avoid duplication.[48,49] According to the study quality assessment, no studies were excluded for a high risk of bias (i.e., NOS scale ≤3) (Supplementary Table 1).

Table 1. Characteristics of included studies.

Authors (Year)	n (SCD/CN)	Women % (SCD/CN)	SCD Age	CN Age	SCD Education	CN Education
Bouhaben et al. (2024)[50]	47/101	70%/61%	69.74 (6.83)	69.0 (7.98)	na (na)	na (na)
Chen et al. (2021)[18]	70/50	67%/64%	67.3 (5.7)	64.5 (4.4)	11.5 (3.3)	11.8 (2.9)
Dhilla Albers et al. (2016)[20]	74/70	23%/71%	77.0 (8.16)	75.0 (8.75)	16.0 (2.9)	17.0 (2.6)
Jobin et al. (2024)[51]	31/73	62% /63%	75.48 (9.22)	72.25 (9.13)	16.25 (2.5)	16.42 (3.62)
Papadatos et al. (2023)[27]	55/55	78%/81%	70.08 (7.0)	69.07 (5.56)	16.97 (3.1)	15.77 (3.24)
Risacher et al. (2017)[52]	10/10	60%/79%	72.2 (6.4)	68.5 (6.9)	17.5 (2.0)	17.6 (2.0)
Schmicker et al. (2023)[53]	17/18	47%/55%	71.7 (7.0)	73.5 (0.48)	13.8 (2.7)	14.3 (2.2)
Sohrabi et al. (2009)[54]	81/63	na / na	65.53 (7.3)	64.66 (7.73)	na (na)	na (na)
Tahmasebi et al. (2019)[48,49]	161/69	51%/63%	66.93 (10.32)	65.5 (10.4)	12.45 (3.55)	12.12 (4.01)
Wang et al. (2021)[55]	84/35	62%/49%	67.0 (5.6)	67.5 (5.3)	11.5 (3.3)	11.8 (2.9)
Weber et al. (2004)[56]	30/30	63%/43%	66.0 (8.9)	65.9 (9.7)	13.9 (3.5)	16.0 (3.0)

Authors (Year)	n (SCD/CN)	Olfactory/ Cognitive Test	SCD Olfactory Score	CN Olfactory Score	SCD Cognitive Score	CN Cognitive Score
Bouhaben et al. (2024)[50]	47/101	SSIT/MoCA	11.23 (3.74)	13.18 (1.61)	28.67 (1.12)	28.96 (1.10)
Chen et al. (2021)[18]	70/50	SSITMMSE	10.8 (2.3)	12.8 (2.0)	27.30 (2.00)	27.20 (1.80)
Dhilla Albers et al. (2016)[20]	74/70	OPID/MMSE	0.67 (0.17)	0.69 (0.17)	28.95 (1.38)	29.45 (0.84)
Jobin et al. (2024)[51]	31/73	OPID/MoCA	10.68 (2.95)	10.79 (2.74)	-0.24 (1.17)	0.29 (0.84)

Papadatos et al. (2023)[27]	55/55	BSIT/MoCA	10.33 (1.69)	10.6 (1.41)	27.22 (1.84)	27.93 (1.50)
Risacher et al. (2017)[52]	10/10	UPSIT/MoCA	35.7 (3.3)	34.5 (2.3)	26.10 (2.30)	26.80 (2.5)
Schmicker et al. (2023)[53]	17/18	SSIT/MMSE	9.41 (1.51)	9.06 (1.47)	28.10 (1.50)	29.10 (1.00)
Sohrabi et al. (2009)[54]	81/63	SSIT/MMSE	12.38 (2.18)	13.12 (1.49)	28.98 (1.06)	29.11 (1.07)
Tahmasebi et al. (2019)[48,49]	161/69	SSIT/MMSE	12.16 (2.57)	12.83 (2.16)	28.84 (1.22)	28.71 (1.00)
Wang et al. (2021)[55]	84/35	SSIT/MMSE	11.1 (2.2)	12.9 (2.0)	26.80 (2.00)	27.00 (1.50)
Weber et al. (2004)[56]	30/30	CC-SIT/MMSE	9.7 (1.7)	10.3 (1.3)	28.50 (1.5)	29.1 (1.00)

Note*:* CC-SIT: Cross-Cultural Smell Identification Test. MoCA: Montreal Cognitive Assessment. MMSE: Mini-Mental State Examination. OPID: Odor Percept Identification. SSIT: Sniffin' Sticks Identification Test. UPSIT: University of Pennsylvania Smell Identification Test. Some studies did not report data on educational level or sex proportion (indicated as 'na'). Additionally, data from Tahmasebi et al. (2019) were provided by the authors and have been used in multiple publications. MoCA score was available for only a subsample of participants (SCD n = 18, CN n = 28 included in Jobin et al., 2024.

3.2 Main Effect (Olfactory Identification)

Meta-analysis of the pooled SMD revealed that SCD groups exhibited significantly lower olfactory identification scores compared to CN groups (SMD= -0.67, 95% CI [-1.31, -0.03], p = .04). Variability in effect sizes across studies was observed (I^2 = 92.1%, τ^2 = .73) and statistically significant (Q(10) = 125.84, p < .001) (Figure 2).



Figure 2: Forest plots of standardized mean differences (SMD) of odor identification and cognitive performances in individuals with SCD vs. CN participants.

Each horizontal line represents the 95% confidence interval (CI) for an individual study, with the square indicating the SMD estimate. The size of the square reflects the weight of the study in the meta-analysis. The diamond at the bottom represents the overall pooled SMD and its 95% CI, estimated using a random-effects model.

3.2.1. Moderator Analysis

Meta-regression analyses were performed to identify potential sources of heterogeneity. *Age* differences between SCD and CN groups did not significantly moderate the observed differences in odor identification performance (β = 0.09, SE = 0.20, 95% CI [-0.36, 0.54], p = .67, R^2 = 0%), suggesting that age alone does not account for the variability in effect sizes across studies (Figure 3). Neither *sex proportion (female %)* (β = -2.72, SE = 1.49, 95% CI [-6.14, 0.70], p = .10, R^2 = 23.52%), *educational level* (years) (β = 0.03, SE = 0.39, 95% CI [-0.90, 0.95], p = .94, R^2 = 0%), or *test modality* (F(4,6) = 1.56, p = .30) significantly moderated the differences observed in odor identification between SCD and CN groups. However, cognitive score on screening measures was a significant moderator (β = -1.79, SE = 0.64, 95% CI [-3.24, -0.34], p = .02, R^2 = 46.47%), indicating that greater cognitive differences between groups were associated with larger olfactory deficits (Figure 4).



Figure 3. Meta-regression and Test Modality Effects on Standardized Mean Difference (SMD) in odor identification across SCD and CN groups.

The four panels depict meta-regression analyses evaluating the impact of age difference (top-left), sex difference (top-right), and education difference (bottom-left). The bottom-right panel shows the effect of test modality on SMD, with different olfactory identification tests (UPSIT, SSIT, OPID, CC-SIT) represented as separate estimates with corresponding 95% confidence intervals. Negative SMD values indicate poorer olfactory performance in SCD group compared to CN group. Overall, none of these potential moderators reached statistical significance. Two studies did not provide information regarding sex distribution,[54] and one did not report educational level;[50,54] these studies were excluded from the respective moderator analyses.



Figure 4. Meta-regression Effect of Cognition on Standardized Mean Difference (SMD) in odor identification across SCD and CN groups.

Negative SMD values suggest poorer olfactory performance in SCD compared to CN. The meta-regression analysis identified cognitive scores on screening tests as a significant moderator (β = -1.79, p = .02), indicating that greater cognitive differences between groups were associated with larger deficits in odor identification.

3.2.2. Publication Bias

Publication bias was assessed using funnel plot inspection, Egger's test, and the trim-and-fill method. Funnel plot symmetry indicated a low likelihood of substantial small-study effects or selective reporting, which was further supported by a non-significant result from Egger's test (t = -1.79, p = .11). The trim-and-fill analysis imputed two additional studies, resulting in an adjusted pooled standardized mean difference of -0.30 (95% CI [-1.03, 0.44], p = .39), which was

substantially weaker and statistically non-significant compared tothe original estimate (SMD = -0.67, 95% CI [-1.31, -0.03], p = .04). This adjustment suggests that the observed effect size might have been overestimated in the presence of publication bias, and raises caution regarding the robustness of the original effect (Figure 5).



Figure 5. Funnel Plots Assessing Publication Bias.

sFor each comparison (olfactory identification and cognition), the left panel displays the funnel plot for publication bias, where each point represents an individual study's SMD plotted against its standard error. The dotted lines indicate the expected distribution of studies in the absence of bias. Symmetry suggests minimal small-study effects or selective reporting. The right panel

shows the trim-and-fill-adjusted funnel plot, with open circles representing imputed studies added to correct for potential asymmetry. The adjusted pooled effect size was smaller than the original estimate, suggesting possible overestimation due to publication bias. The wide confidence interval of the adjusted estimate includes zero, indicating that the association may not be significant after accounting for missing studies.

3.3. Main Effect (Cognitive Score on Screening Tests)

The meta-analysis of cognitive differences between SCD and CN also revealed a significant effect (SMD = -0.31, 95% CI [-0.53, -0.08], p = .01). Heterogeneity was moderate (I^2 = 39.3%, τ^2 = .05, p = .21) but not statistically significant (Q(10) = 16.48, p = 0.09), indicating that cognitive differences between SCD and CN are consistent across studies (Figure 2). As heterogeneity remained below the critical threshold ($I^2 < 75\%$), no moderator analysis was deemed necessary. Overall, the odor identification differences (SMD = -0.67) show a larger effect size than cognitive differences (SMD = -0.31).

3.3.1. Publication Bias

Funnel plot inspection showed no strong evidence of asymmetry, and Egger's test was again non-significant (t = -1.88 p = .09), indicating a low likelihood of publication bias (Figure 4). The trim-and-fill analysis imputed four additional studies, resulting in an adjusted pooled SMD of -0.19 (95% CI [-0.42, 0.05], p = .11), which, although weaker and non-significant, remained in the same direction.

4. Discussion

Here we report that individuals with SCD exhibited lower odor identification scores compared to CN participants. Moderator analyses indicated that cognitive performance was associated with olfactory scores, whereas age, sex, education, and test modality did not. These findings confirm that individuals with SCD exhibit significantly reduced odor identification performance compared to CN participants without cognitive complaints, extending the hypothesis that olfactory deficits may serve as an early marker of the presence of AD pathology and future cognitive decline during Stage 2 (Subjective Cognitive Decline). The effect size for group differences in odor identification (SMD = -0.67) was larger than that observed for general cognitive screening tests (SMD = -0.31), suggesting that olfactory impairment may be a more sensitive measure of subtle neurodegenerative changes in individuals with SCD. Heterogeneity was observed across studies in odor identification differences, which could not be explained by age, sex proportion, education, or test modality. Cognitive performance across groups significantly moderated olfactory scores, suggesting that olfactory performance may reflect cognitive decline that remains within the normal range on standard neuropsychological assessments in the preclinical SCD stage. Although publication bias did not appear to have strongly influenced the results, the high level of heterogeneity highlights the need for further investigation into additional contributing factors, including genetic predispositions and fluid and/or imaging biomarkers of neurodegeneration, which may account for the variability in olfactory identification deficits in SCD populations.

This meta-analysis confirmed that odor identification is reduced in SCD compared to CN participants, confirming a trend observed in an initial meta-analysis published in 2021.[36] In the context of the AD continuum, this finding suggests that odor identification is impaired prior to

the onset of cognitive deficits associated with MCI. This result aligns with studies demonstrating associations between olfactory scores and AD tau or amyloid pathology biomarkers measured in cognitively unimpaired,[28,57,58] and non-demented individuals.[59,60] A longitudinal study showed that lower olfactory identification score correlates with baseline tau accumulation in primary olfactory region and predicted accelerated progression of tau pathology in these regions ~2.5 years after.[28] Similarly, olfactory identification has been associated with hippocampal volume and entorhinal cortex thickness in patients with MCI[20–26] and individuals with SCD without cognitive impairment.[27] These findings suggest that odor identification tests could be among the earliest objective measurements of AD-related damage to brain regions involved in olfactory processing, occurring before the observable cognitive deficits.

Moderator analyses revealed that age, sex, education, and olfactory test modality did not moderate the effect size. However, larger group differences on cognitive screening tests were associated with larger differences in odor identification performance. Since all participants were cognitively normal by definition, this result suggests that odor identification may serve as a marker of subtle cognitive changes that remain undetected by standard cognitive screening tools. This interpretation is consistent with a meta-analysis showing that odor identification scores are associated with declarative memory in CN older adults.[61] Longitudinal studies have demonstrated the predictive value of odor identification scores on future cognitive decline[29,62–65] and conversion to MCI.[30,32,33] Taken together, these findings support the role of odor identification as an early indicator of cognitive changes that may precede MCI in at-risk individuals . For instance, lower olfactory identification scores in carriers of the ε4 allele of the Apolipoprotein E (ApoE) gene have been associated with long-term episodic memory decline.[63]

It is important to note that reduced odor identification function is not specific to AD and should not be used as a stand-alone diagnostic tool. Several other conditions can impair olfaction, including neurological disorders such as Parkinson's disease,[66,67] and traumatic brain injury,[68–70]; as well as non-neurological conditions like chronic rhinosinusitis,[71] among others.[72] Therefore, interpretation of olfactory testing in the context of early AD detection must be approached with caution. Two meta-analyses demonstrated that among olfactory functions, olfactory identification is more specifically damaged in AD[13] and MCI[14] compared to a broader loss of smell observed in conditions affecting the peripherical olfactory system[72] or in Parkinson's disease.[13] Furthermore, a recent study showed that while a higher odor identification score was associated with a higher probability of not having MCI (79%), lower score has limited sensitivity (58%) in distinguishing MCI from SCD.[73] This suggests that the absence of an olfactory identification deficit lowers the likelihood of AD, whereas a reduced score should lead to further investigation. In such cases, more invasive and expensive diagnostic tools—such as, blood-based or CSF biomarkers, structural MRI, PET scans, comprehensive neuropsychological testing, and otorhinolaryngological examination—should be considered. Odor identification might serve as a low-cost, non-invasive first-line screening tool for brain health, and low score should trigger more in-depth evaluation to rule out other modifiable causes of olfactory dysfunction that may benefit from early intervention addressing social isolation, auditive and visual impairments, cardiovascular risk factors, depression, physical inactivity, among others.[74]

Our findings support the inclusion of an odor identification testing as an additional risk factor in the SCD+ framework, which aims to refine the identification of individuals at elevated risk of AD. This framework also includes criteria such as memory-specific complaints, onset of SCD within the past five years, age over 60, external confirmation of cognitive decline, and

clinical help-seeking.[7] Given the associations between olfactory deficits and AD biomarkers,[28,57,75] medial temporal atrophy,[18,20,23,24,26] and longitudinal cognitive decline,[29,30,32,33,62–65] integrating odor identification into the SCD+ criteria could enhance the stratification of risk for preclinical AD. Future studies should investigate whether combining olfactory testing with the SCD+ framework improves the prediction of progression to MCI and AD dementia.

The main limitation of this meta-analysis is that while meta-regression identified cognitive performance as a significant moderator, other potential contributors to heterogeneity such as genetic risk (e.g., APOE-ε4 status), neuropathological burden, or environmental factors were not assessed due to limited available data. These potential variables could have enhanced the comprehension of the significant heterogeneity observed in odor identification differences between groups ($I^2 = 92.1\%$). Future research should incorporate these variables, particularly amyloid and tau biomarkers, to strengthen the specificity of olfactory impairment as a preclinical marker AD.[1]

5. Conclusion

The presence of odor identification impairments, observed alongside normal-range of cognitive performance in individuals with SCD, reinforces the hypothesis that olfactory impairment may constitute an early marker of AD preceding MCI. These findings align with previous research associating odor identification impairment with AD biomarkers and longitudinal cognitive decline. Future longitudinal research should explore whether combining odor identification testingwith the SCD+ criteria improves the accuracy and precision of predicting AD pathology, future cognitive decline, and progression to MCI or AD dementia.

6. Acknowledgements

Jobin is supported by scholarships from the Canadian Institutes of Health Research (CIHR), the Fonds de Recherche Québec (FRQ) Santé, the Quebec Bio-Imaging Network, the Université du Québec à Trois-Rivières, and MITACS. Zigrand is supported by the FRQ Santé. Frasnelli is supported by CIHR (AFF_173514), FRQ Santé (352197), and the Natural Sciences and Engineering Research Council of Canada (NSERC; RGPIN-2022-04813). Boller is supported by the FRQ Société et culture (2023-NP-311368) and Réseau Québecois de recherche sur le vieillissement. Albers received support from the NIH (R42 AG062130 and U01DC019579).

7. Conflict of Interest

M.W.A. is a co-founder and shareholder of Aromha, Inc. He consults for Sudo Biosciences, Merck, and Bristol Myers Squibb; has been sponsored for research presentations to Incyte; and has received in-kind support from Eli Lilly and International Fragrances and Flavors.

8. References

1. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's & Dementia*. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018

2. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis. *JAMA*. 2015;313(19):1924. doi:10.1001/jama.2015.4668

3. Jia J, Ning Y, Chen M, et al. Biomarker Changes during 20 Years Preceding Alzheimer's Disease. *N Engl J Med*. 2024;390(8):712-722. doi:10.1056/NEJMoa2310168

4. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. *The Lancet Neurology*. 2013;12(4):11.

5. Mintun MA, Lo AC, Evans CD, et al. Donanemab in Early Alzheimer's Disease. *n engl j med*. 2021;384(18):1691-1704. doi:10.1056/NEJMoa2100708

6. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. *n engl j med*. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948

7. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimer's & Dementia*. 2014;10(6):844-852. doi:10.1016/j.jalz.2014.01.001

8. Jessen F, Amariglio RE, Buckley RF, et al. The characterisation of subjective cognitive decline. *The Lancet Neurology*. 2020;19(3):271-278. doi:10.1016/S1474-4422(19)30368-0

9. Ebenau JL, Timmers T, Wesselman LMP, et al. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. *Neurology*. 2020;95(1):e46-e58. doi:10.1212/WNL.0000000000009724

10. Liew TM. Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia. *Alz Res Therapy*. 2020;12(1):135. doi:10.1186/s13195-020-00699-y

11. Janssen O, Jansen WJ, Vos SJB, et al. Characteristics of subjective cognitive decline associated with amyloid positivity. *Alzheimer's & Dementia*. 2021;18(10):1832-1845. doi:10.1002/alz.12512

12. Pavisic IM, Lu K, Keuss SE, et al. Subjective cognitive complaints at age 70: associations with amyloid and mental health. *J Neurol Neurosurg Psychiatry*. 2021;92(11):1215-1221. doi:10.1136/jnnp-2020-325620

13. Rahayel S, Frasnelli J, Joubert S. The effect of Alzheimer's disease and Parkinson's disease on olfaction: A meta-analysis. *Behavioural Brain Research*. 2012;231(1):60-74. doi:10.1016/j.bbr.2012.02.047

14. Roalf DR, Moberg MJ, Turetsky BI, et al. A quantitative meta-analysis of olfactory dysfunction in mild cognitive impairment. *J Neurol Neurosurg Psychiatry*. 2017;88(3):226-232. doi:10.1136/jnnp-2016-314638

15. Albers MW, Gilmore GC, Kaye J, et al. At the interface of sensory and motor dysfunctions and Alzheimer's disease. *Alzheimer's & Dementia*. 2015;11(1):70-98. doi:10.1016/j.jalz.2014.04.514

16. Murphy C. Olfactory and other sensory impairments in Alzheimer disease. *Nat Rev Neurol*. 2019;15(1):11-24. doi:10.1038/s41582-018-0097-5

17. Jobin B, Boller B, Frasnelli J. Smaller grey matter volume in the central olfactory system in mild cognitive impairment. *Experimental Gerontology*. 2023;183:112325. doi:10.1016/j.exger.2023.112325

18. Chen B, Wang Q, Zhong X, et al. Structural and Functional Abnormalities of Olfactory-Related Regions in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease. *International Journal of Neuropsychopharmacology*. 2021;25(5):361-374. doi:10.1093/ijnp/pyab091

19. Vasavada MM, Wang J, Eslinger PJ, et al. Olfactory cortex degeneration in Alzheimer's disease and mild cognitive impairment. *Journal of Alzheimer's disease*. 2015;45(3):947-958. doi:10.3233/JAD-141947

20. Dhilla Albers A, Asafu-Adjei J, Delaney MK, et al. Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly: POEM: Odor Memory Biomarker in Normal Elderly. *Ann Neurol*. 2016;80(6):846-857. doi:10.1002/ana.24792

21. Kose Y, Hatamoto Y, Takae R, et al. Association between the inability to identify particular odors and physical performance, cognitive function, and/or brain atrophy in community-dwelling older adults from the Fukuoka Island City study. *BMC Geriatr*. 2021;21(1):421. doi:10.1186/s12877-021-02363-y

22. Hagemeier J, Woodward MR, Rafique UA, et al. Odor identification deficit in mild cognitive impairment and Alzheimer's disease is associated with hippocampal and deep gray matter atrophy. *Psychiatry Research: Neuroimaging*. 2016;255:87-93. doi:10.1016/j.pscychresns.2016.08.003

23. Kjelvik G, Saltvedt I, White LR, et al. The brain structural and cognitive basis of odor identification deficits in mild cognitive impairment and Alzheimer's disease. *BMC Neurol*. 2014;14(1):168. doi:10.1186/s12883-014-0168-1

24. Murphy C, Jernigan TL, Fennema-Notestine C. Left hippocampal volume loss in Alzheimer's disease is reflected in performance on odor identification: A structural MRI study. *J Int Neuropsychol Soc*. 2003;9(3):459-471. doi:10.1017/S1355617703930116

25. Yoshii F, Onaka H, Kohara S, Ryo M, Takahashi W. Association of Smell Identification Deficit with Alzheimer's Disease Assessment Scale-Cognitive Subscale, Japanese Version Scores and Brain Atrophy in Patients with Dementia. *Eur Neurol*. 2019;81(3-4):145-151. doi:10.1159/000501311

26. Yu H li, Chen Z juan, Zhao J wei, Duan S rong, Zhao J kun. Olfactory Impairment and Hippocampal Volume in a Chinese MCI Clinical Sample. *Alzheimer Disease & Associated Disorders*. 2019;33(2):124-128. doi:10.1097/WAD.0000000000000305

27. Papadatos Z, Phillips NA. Olfactory function reflects episodic memory performance and atrophy in the medial temporal lobe in individuals at risk for Alzheimer's disease. *Neurobiology of Aging*. 2023;128:33-42. doi:10.1016/j.neurobiolaging.2023.04.001

28. Diez I, Ortiz-Terán L, Ng TSC, et al. Tau propagation in the brain olfactory circuits is associated with smell perception changes in aging. *Nat Commun*. 2024;15(1):4809. doi:10.1038/s41467-024-48462-3

29. Devanand DP, Lee S, Manly J, et al. Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community. *Neurology*. 2015;84(2):182-189. doi:10.1212/WNL.0000000000001132

30. Roberts RO, Christianson TJ, Kremers WK, et al. Association between olfactory dysfunction and amnestic mild cognitive impairment and Alzheimer disease dementia. *JAMA neurology*. 2016;73(1):93-101.

31. Swan GE, Carmelli D. Impaired Olfaction Predicts Cognitive Decline in Nondemented Older Adults. *Neuroepidemiology*. 2002;21(2):58-67. doi:10.1159/000048618

32. Wheeler PL, Murphy C. Olfactory Measures as Predictors of Conversion to Mild Cognitive Impairment and Alzheimer's Disease. *Brain Sciences*. 2021;11(11):1391. doi:10.3390/brainsci11111391

33. Wilson RS, Schneider JA, Arnold SE, Tang Y, Boyle PA, Bennett DA. Olfactory Identification and Incidence of Mild Cognitive Impairment in Older Age. *Arch Gen Psychiatry*. 2007;64(7):802. doi:10.1001/archpsyc.64.7.802

34. Devanand DP, Liu X, Cohen H, et al. Long-Term Test–Retest Reliability of the UPSIT in Cognitively Intact Older Adults. *Chemical senses*. 2019;44(6):365-369.

35. Conti MZ, Vicini-Chilovi B, Riva M, et al. Odor Identification Deficit Predicts Clinical Conversion from Mild Cognitive Impairment to Dementia Due to Alzheimer's Disease. *Archives of Clinical Neuropsychology*. 2013;28(5):391-399. doi:10.1093/arclin/act032

36. Jobin B, Zahal R, Bussières EL, Frasnelli J, Boller B. Olfactory Identification in Subjective Cognitive Decline: A Meta-Analysis. Pike K, ed. *JAD*. 2021;79(4):1497-1507. doi:10.3233/JAD-201022

37. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment: MOCA: A BRIEF SCREENING TOOL FOR MCI. *Journal of the American Geriatrics Society*. 2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x

38. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." *Journal of Psychiatric Research*. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6

39. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. 'Sniffin'sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. *Chemical senses*. 1997;22(1):39-52.

40. Jobin B, Magdamo C, Delphus D, et al. The AROMHA brain health test is a remote olfactory assessment to screen for cognitive impairment. *Scientific Reports*. 2025;15(9290).

41. Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. *The Laryngoscope*. 1984;94(2):176-178.

42. Doty RL, Marcus A, William Lee W. Development of the 12-Item Cross-Cultural Smell Identification Test(CC-SIT). *Laryngoscope*. 1996;106(3):353-356. doi:10.1097/00005537-199603000-00021

43. Zeng X, Zhang Y, Kwong JSW, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review: Methodological quality assessment tools. *Journal of Evidence-Based Medicine*. 2015;8(1):2-10. doi:10.1111/jebm.12141

44. Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. *Ottawa: Ottawa Hospital Research Institute*. Published online 2011.

45. Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. *Statistics in medicine*. 2001;20(24):3875-3889.

46. IntHout J, Ioannidis JPA, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. *BMJ Open*. 2016;6(7):e010247. doi:10.1136/bmjopen-2015-010247

47. Veroniki AA, Jackson D, Viechtbauer W, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. *Research Synthesis Methods*. 2016;7(1):55-79. doi:10.1002/jrsm.1164

48. Tahmasebi R, Zehetmayer S, Stögmann E, Lehrner J. Awareness of Olfactory Dysfunction in Subjective Cognitive Decline, Mild Cognitive Decline, and Alzheimer's Disease. *Chem Percept*. Published online June 24, 2019. doi:10.1007/s12078-019-09267-7

49. Tahmasebi R, Zehetmayer S, Pusswald G, Kovacs G, Stögmann E, Lehrner J. Identification of odors, faces, cities and naming of objects in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer´ s disease: a longitudinal study. *International psychogeriatrics*. 2019;31(4):537-549.

50. Bouhaben J, Delgado-Lima AH, Delgado-Losada ML. Olfactory Identification as a Biomarker for Cognitive Impairment: Insights from Healthy Aging, Subjective Cognitive Decline, and Mild Cognitive Impairment. *EJIHPE*. 2024;14(12):2978-3000. doi:10.3390/ejihpe14120196

51. Jobin B, Magdamo C, Delphus D, et al. AROMHA Brain Health Test: A Remote Olfactory Assessment as a Screen for Cognitive Impairment. Published online August 6, 2024:2024.08.03.24311283. doi:10.1101/2024.08.03.24311283

52. Risacher SL, Tallman EF, West JD, et al. Olfactory identification in subjective cognitive decline and mild cognitive impairment: Association with tau but not amyloid positron emission tomography. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*. 2017;9:57-66.

53. Schmicker M, Frühling I, Menze I, et al. The Potential Role of Gustatory Function as an Early Diagnostic Marker for the Risk of Alzheimer's Disease in Subjective Cognitive Decline. *Journal of Alzheimer's Disease Reports*. 2023;7(1):249-262. doi:10.3233/ADR220092

54. Sohrabi HR, Bates KA, Rodrigues M, et al. Olfactory dysfunction is associated with subjective memory complaints in community-dwelling elderly individuals. *Journal of Alzheimer's Disease*. 2009;17(1):135-142.

55. Wang Q, Chen B, Zhong X, et al. Olfactory Dysfunction Is Already Present with Subjective Cognitive Decline and Deepens with Disease Severity in the Alzheimer's Disease Spectrum. *JAD*. 2021;79(2):585-595. doi:10.3233/JAD-201168

56. Weber MT. *Odor Memory in Older Adults with and without Cognitive Impairments*. Ph.D. State University of New York at Albany; 2003. https://search.proquest.com/docview/304658367?accountid=12543

57. Lafaille-Magnan ME, Poirier J, Etienne P, et al. Odor identification as a biomarker of preclinical AD in older adults at risk. *Neurology*. 2017;89(4):327-335. doi:10.1212/WNL.0000000000004159

58. Tian Q, Bilgel M, Moghekar AR, Ferrucci L, Resnick SM. Olfaction, Cognitive Impairment, and PET Biomarkers in Community-Dwelling Older Adults. *JAD*. 2022;86(3):1275-1285. doi:10.3233/JAD-210636

59. Dong Y, Li Y, Liu K, et al. Anosmia, mild cognitive impairment, and biomarkers of brain aging in older adults. *Alzheimer's & Dementia*. 2023;19(2):589-601. doi:10.1002/alz.12777

60. Ramirez-Gomez L, Albers MW, Baena A, et al. Olfactory Function and Markers of Brain Pathology in Non-Demented Individuals with Autosomal Dominant Alzheimer's Disease. *JAD*. 2022;88(2):721-729. doi:10.3233/JAD-220075

61. Jobin B, Roy-Côté F, Frasnelli J, Boller B. Olfaction and Declarative Memory in Aging: A Meta-analysis. *Chemical Senses*. 2023;48:bjad045. doi:10.1093/chemse/bjad045

62. Dintica CS, Marseglia A, Rizzuto D, et al. Impaired olfaction is associated with cognitive decline and neurodegeneration in the brain. *Neurology*. 2019;92(7):e700-e709. doi:10.1212/WNL.0000000000006919

63. Olofsson JK, Larsson M, Roa C, Wilson DA, Jonsson Laukka E. Interaction Between Odor Identification Deficit and APOE4 Predicts 6-Year Cognitive Decline in Elderly Individuals. *Behav Genet*. 2020;50(1):3-13. doi:10.1007/s10519-019-09980-9

64. Sohrabi HR, Bates KA, Weinborn MG, et al. Olfactory discrimination predicts cognitive decline among community-dwelling older adults. *Transl Psychiatry*. 2012;2(5):e118-e118. doi:10.1038/tp.2012.43

65. Windon MJ, Kim SJ, Oh ES, Lin SY. Predictive value of olfactory impairment for cognitive decline among cognitively normal adults. *The Laryngoscope*. 2019;130(4):840-847. doi:10.1002/lary.28166

66. Doty RL. Olfactory dysfunction in Parkinson disease. *Nature Reviews Neurology*. 2012;8(6):329-339. doi:10.1038/nrneurol.2012.80

67. Fullard ME, Morley JF, Duda JE. Olfactory Dysfunction as an Early Biomarker in Parkinson's Disease. *Neurosci Bull*. 2017;33(5):515-525. doi:10.1007/s12264-017-0170-x

68. Lecuyer Giguère F, Frasnelli A, De Guise É, Frasnelli J. Olfactory, cognitive and affective dysfunction assessed 24 hours and one year after a mild Traumatic Brain Injury (mTBI). *Brain Injury*. 2019;33(9):1184-1193. doi:10.1080/02699052.2019.1631486

69. Zigrand C, Jobin B, Lecuyer Giguère F, Giguère JF, Boller B, Frasnelli J. Olfactory perception in patients with a mild traumatic brain injury: a longitudinal study. *Brain Injury*. 2022;36(8):985-990. doi:10.1080/02699052.2022.2109734

70. Proskynitopoulos P, Stippler M, Kasper E. Post-traumatic anosmia in patients with mild traumatic brain injury (mTBI): A systematic and illustrated review. *Surg Neurol Int*. 2016;7(11):263. doi:10.4103/2152-7806.181981

71. Rombaux P, Huart C, Levie P, Cingi C, Hummel T. Olfaction in chronic rhinosinusitis. *Current allergy and asthma reports*. 2016;16:1-12.

72. Patel ZM, Holbrook EH, Turner JH, et al. International consensus statement on allergy and rhinology: Olfaction. *Int Forum Allergy Rhinol*. 2022;12(4):327-680. doi:10.1002/alr.22929

73. Jobin B, Philips N, Frasnelli J, Boller B, CIMA-Q. Associations between declarative memory and olfactory identification in older adults at risk for alzheimer's disease: preliminary results from the cima-q cohort. In: International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (ADPD) 2025; 2025.

74. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. *The Lancet*. 2024;404(10452):572-628.

75. Klein J, Yan X, Johnson A, et al. Olfactory Impairment Is Related to Tau Pathology and Neuroinflammation in Alzheimer's Disease. Gordon B, ed. *JAD*. 2021;80(3):1051-1065. doi:10.3233/JAD-201149